Ascendis Pharma (ASND) Reports Q3 Loss of EUR0.30/Share

Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR0.30), versus (EUR0.18) reported last year. Revenue for the quarter came in at EUR2.1 million, versus EUR3.3 million reported last year.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Is the S&P 500 in an "earnings bubble"? Goldman weighs in
• Versant Media Group (VSNT) PT Lowered to $43 at Goldman Sachs
• Jana Partners urges Cooper Companies to replace CEO and explore asset sales